Sanofi SA (LTS:0A2V)
$ 49 0 (0%) Market Cap: 122.85 Bil Enterprise Value: 141.18 Bil PE Ratio: 28.19 PB Ratio: 1.63 GF Score: 87/100

Sanofi SA at Credit Suisse Healthcare Conference (Virtual) Transcript

Nov 11, 2020 / 07:45PM GMT
Release Date Price: $47.64
Jo Walton;dit Suisse AG
CrÃ;Research Division - MD

© -

Good afternoon, and good evening. It's my pleasure -- I'm Jo Walton, and it's my pleasure with my colleague Matthew Weston here to introduce Dietmar Berger as our speaker from Sanofi. We also have the main Sanofi IR team available should we have any broader questions.

Dietmar is the Head of -- Global Head of Clinical Development and the Chief Medical Officer. He has had wide experience before joining Sanofi in 2019. And in fact, coming back to Sanofi or coming to Sanofi here, he works once again with John Reed, who he worked with at Roche.

Questions & Answers

Jo Walton;dit Suisse AG
CrÃ;Research Division - MD

© -

I'm going to start with a broad question on R&D. And then we're going to move on to look at some of the individual products. We've had an extensive disclosure this summer through a series of R&D meetings, and we're hoping to build on that disclosure with more Q&A today.

So firstly, my question to you is

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot